Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Open accessThe DOI matches its Crossref record; 183 of the 192 references it cites were found in a registry or an index; 48 of the 182 sources its claims cite were checked for support.
Abstract
Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative.
Overview
CoChat Summary
TL;DR
This review interrogates the accuracy of global and multi-national estimates of serious fungal disease burden generated through the Leading International Fungal Education (LIFE) initiative. It summarizes estimates from 43 published country reports and highlights wide variation, data gaps, and likely underestimation of fungal disease burden.
Key findings
- Recent global estimates include 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of *Pneumocystis jirovecii* pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma, and ~1,000,000 cases of fungal keratitis annually.
- Across LIFE country papers, candidaemia burden was 159,253 cases in 39 countries, invasive aspergillosis was 81,927 cases in 40 countries, and *Pneumocystis jirovecii* pneumonia was 133,487 cases in 40 papers; the highest candidaemia prevalence was reported in Pakistan (38,795 cases, 21 per 100,000).
- Chronic pulmonary aspergillosis estimates were highest in India (209,147) and Nigeria (120,753), with an overall incidence of 22 cases per 100,000 (14.2–30.59 95% CI); ABPA was estimated at 3,550,157 cases and SAFS at 4,125,428 cases across 43 countries.
- Tinea capitis was estimated at 21,073,423 cases in just 16 countries, with Nigeria alone accounting for 15,581,400 cases; global recurrent vulvovaginal candidiasis prevalence was estimated at about 134,000,000 cases.
Methods
- Narrative review of 43 published papers within the LIFE initiative, covering >2000 million people (29% of the world population), with the LIFE portal having facilitated estimates for over 5.7 billion people (>80% of the world’s population).
- The paper describes how country-level burden estimates were derived for specific fungal diseases, using published epidemiological data, modelling assumptions, and at-risk population denominators.
- Main analysis is descriptive and comparative: it aggregates country estimates, examines differences by region, country, and at-risk group, and discusses strengths and weaknesses of the estimation methods.
Limitations
- The paper states that a precise estimate of global prevalence and incidence for each fungal infection remains unknown, and data are scanty in most countries, especially in the developing world.
- It states that knowledge is impaired by lack of regular national surveillance, no obligatory reporting of fungal diseases, poor clinician suspicion outside specialised units, poor diagnostic test performance, and few well-designed published studies; estimates are not intended as a substitute for high-quality epidemiological study or comprehensive surveillance.
- It also states that comparisons across countries are difficult because recent local epidemiological data were available for only some countries, data quality varies, not all institutions report infections, and many low- and low-middle-income countries lack blood culture systems; the text makes evident that country estimates rely on heterogeneous assumptions and uniform rates in places, such as 5 per 100,000 for candidaemia when local data were unavailable and 6% for recurrent vulvovaginal candidiasis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
33 Valid · 8 Not valid · 70 Not checked · 75 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In particular, resistance to fluconazole is common [30,43,44]”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
What the sources say
- Not checked — no full text of the sourcecites [30] Arendrup M.C. Candida and Candidaemia: Susceptibility and Epidemiology Dan. Med. J. 2013 60 1 32 24192246
- Disputedcites [43] Hii I.M. Chang H.L. Lin L.C. Lee Y.L. Liu Y.M. Liu C.E. Chen C.H. Cheng Y.R. Chang C.Y. Changing epidemiology of candidemia in a medical center in middle Taiwan J. Microbiol. Immunol. Infect. 2015 48 306 315 10.1016/j.jmii.2013.08.017 24113067 sourceExperimental — accuracy not yet measured
The Discussion reports an overall fluconazole resistance rate of 4.95% among the clinical Candida isolates, contrary to the unqualified claim that resistance is common. The Antifungal susceptibility section distinguishes resistance from reduced susceptibility: only 4.4% of C. glabrata isolates were resistant, although 66.7% were dose-dependent susceptible. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [44] Al Thaqafi A.H.O. Farahat F.M. Al Harbi M.I. Al Amri A.F.W. Perfect J.R. Predictors and outcomes of Candida bloodstream infection: Eight-year surveillance, western Saudi Arabia Int. J. Infect. Dis. 2014 21 5 9 10.1016/j.ijid.2013.12.012 24468816 source
The Discussion describes a high level of fluconazole resistance as alarming. The Results report low in vitro susceptibility among Candida bloodstream isolates in the hospital studied, supporting the claim in that setting. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Modelling with existing outcome data shows that mortality associated with these priority fungal diseases concurrently with the Joint United Nations Program on HIV/AIDS (UNAIDS) 90-90-90 campaign could save over 1.6 million lives of persons living with HIV globally over the next five years [2].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The burden of infectious (all-cause, including fungal) keratitis in Mexico was estimated based on the prevalence of reported in China (0.148%) [150].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.6. Fungal Keratitis
What the sources say
- Supportedcites [150] Cao J. Yang Y. Yang W. Wu R. Xiao X. Yuan J. Xing Y. Tan X. Prevalence of infectious keratitis in Central China BMC Ophthalmol. 2014 14 1 6 10.1186/1471-2415-14-43 24690368 PMC3976152 source
The Abstract Results report an infectious keratitis prevalence of 0.148% in Central China and separately include fungal keratitis among its causes. The Mexico estimate is the citing authors’ use of that figure, not a result attributed to this source. (LLM, conf=0.92)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population).”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > Abstract
What the sources say
- Partly supportedcites [14] Denning D.W. Calling upon all public health mycologists Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 923 924 10.1007/s10096-017-2909-8 28150046 sourceExperimental — accuracy not yet measured
The paper describes systematic country-by-country estimates of serious fungal infections and links to the LIFE site for completed estimates (p. 1). It does not state that the portal facilitated this work since 2013 or that the estimates covered over 5.7 billion people (>80% of the world’s population); its stated figure of 883 million people refers only to the current 14-country series (p. 1). (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), asthma and the increasing incidence of cancers are the major drivers of fungal infections in both developed and developing countries globally [1,2,3,4,5,6].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Brown G.D. Denning D.W. Gow N.A.R. Levitz S.M. Netea M.G. White T.C. Hidden Killers: Human Fungal Infections Sci. Transl. Med. 2012 4 1 9 10.1126/scitranslmed.3004404 23253612 source
- Partly supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 sourceExperimental — accuracy not yet measured
The Introduction identifies major fungal diseases complicating HIV, and the section on chronic pulmonary aspergillosis complicating tuberculosis in HIV-positive patients names TB and COPD as underlying pulmonary disorders (page unavailable). The paper does not identify asthma or increasing cancer incidence as drivers, nor does it establish that the listed conditions are the major drivers of fungal infections globally across developed and developing countries. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [3] Armstrong-James D. Meintjes G. Brown G.D. A neglected epidemic: Fungal infections in HIV/AIDS Trends Microbiol. 2014 22 120 127 10.1016/j.tim.2014.01.001 24530175 source
- Not checked — no full text of the sourcecites [4] Guinea J. Torres-Narbona M. Gijón P. Muñoz P. Pozo F. Peláez T. de Miguel J. Bouza E. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome Clin. Microbiol. Infect. 2010 16 870 877 10.1111/j.1469-0691.2009.03015.x 19906275 source
- Not checked — no full text of the sourcecites [5] Marr K.A. Carter R.A. Boeckh M. Martin P. Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors Blood 2002 100 4358 4366 10.1182/blood-2002-05-1496 12393425 source
- Not checked — no full text of the sourcecites [6] Limper A.H. Adenis A. Le T. Harrison T.S. Fungal infections in HIV/AIDS Lancet Infect. Dis. 2017 10.1016/S1473-3099(17)30303-1 28774701 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
52 more claims · 6 with their cited sources checked
Create a free account to see all 186 claims and to verify the 39 references still open.
- Probably not a substantial claim. 80
- It may state two separate claims as one. 82
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the target organ of A. fumigatus is the lungs, Aspergillus is known to be angiotropic and has an affinity for host vasculature. As growing hyphae penetrate pulmonary tissues, they can invade the endothelial lining of nearby blood vessels and break off into circulation, causing sepsis and dissemination accompanied by thrombosis, hemorrhagic infarction and invasion of distant organs [8, 164”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year, primarily in those with some compromised immune function [1].”
From Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 (2022) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“In healthy individuals, these conidia are rapidly cleared, but in the case of immunocompromised patients, conidia can germinate and develop filamentous hyphae [1, 166]. This fungal growth can result in invasive aspergillosis: a severe and aggressive fungal disease characterized by tissue damage, necrosis and hypoxia [8, 164, 167].”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
In the citing paper
“Candida albicans the primary species responsible for mucosal disease”
From Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole (2022) · cites this paper as Bongomin et al. 2017
In the citing paper
“Deep-seated candidiasis, arising from direct inoculation or hematogenous dissemination of Candida into normally sterile body sites, is often difficult to diagnose and may affect a population as large as that of candidemia [4,5,6].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“28,447 [2.5% of 1,136,092] (62 per 100,000) patients with ABPA”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“37,491 [3.33% of 1,136,092] (37.5 per 100,000) with severe asthma with fungal sensitisation (SAFS)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“Average incidence is 154 cases per 100,000 (SD ± 654)”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“the highest incidence rates reported in United Kingdom (654 per 100,000)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“The total burden of candidaemia is 159,253 cases across these 39 countries with available data.”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“Europe (n = 1 country, 420,549 cases)”
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundHidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284 · cited 1×
“Pneumocystis jirovecii pneumonia is emerging as a leading cause of infection in HIV/AIDS patients [1].”
BackgroundSelf-citationGlobal burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., Denning, D. W., Loyse, A., & Boulware, D. R. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30243-8 · Cited by 1,861 · cited 1×
“[8], Fungal Infection Trust [12], Global Action Fund for Fungal Infection (GAFFI) Roadmap [9], and van de Sande [13].”
BackgroundSelf-citationGlobal asthma prevalence in adults: findings from the cross-sectional world health survey
To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., & Boulet, L.-P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-204 · Cited by 1,521 · cited 1×
“6% respectively among individuals aged 18 to 45 years [142].”
BackgroundKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundSobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
(2006) · PubMed · Cited by 906
Research works printed but not linked: 6
- Denning D.W. Global fungal Burden Mycoses 2013 56 13
- The Fungal Infection Trust How common are fungal diseases? Proceedings of the Fungal Research Trust 20th Anniversary Meeting London, UK 18 June 2011 updated August 2017, London, UK 2017 Available online: http://www.fungalinfectiontrust.org/wp-content/uploads/2015/12/How-Common-are-Fungal-Diseases-v12.2.pdf (accessed on 12 September 2017)
- Jayasekera P.I. Denning D. Perera P. Fernando A. Kudavidanage S. The burden of serious fungal infections in Sri Lanka Mycoses 2013 56 103
- Beardsley J. Denning D. Chau N. Crump J. Day J. Estimating the burden of fungal diseases in Vietnam Eur. Conf. Clin. Microbiol. Infect. Dis. Published Online First: 2014 Available online: http://eccmid.meetingxpert.net/ECCMID_699/poster_108496/program.aspx/anchor108496 (accessed on 31 August 2017)
- Gugnani H.C. Denning D.W. Rahim R. Sadat A. Belal M. Mahbub M.S. Medina N. Samayoa B. Lau-Bonilla D. Denning D.W. Burden of serious fungal infections in Bangladesh Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 965 969 10.1007/s10096-017-2921-z 28161744 · DOI · Paper page
- Samayoa B. Isern V. Serra L. Rivera B.E. Nikiforov M. Arathoon E. Samayoa C. Vallès X. Prieto L. Álvarez C. Preliminary results of a prospective cohort of HIV+ patients in Guatemala Proceedings of the XVIII International AIDS Conference Vienna, Austria 18–23 July 2010
Cited by
Items 2,601–2,700 of 2,932
Jackson, L. A., Njerawana, S., Chebon, S., & Bii, C. C. (2024) · F1000Research · doi:10.12688/f1000research.156469.1
Lung Immunity to Fungal Infections by Macrophages: Mechanisms and Implications
Sharma, J., Kulkarni, N. A., & Nanjappa, S. G. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1007542
Roy, A., Sharma, S., Dey, J., Yadav, S., & Prasad, H. K. (2024) · Advances in chemical and materials engineering book series · doi:10.4018/979-8-3693-6240-2.ch009 · Cited by 2
Hu, X., Du, M., Tao, C., Wang, J., Zhang, Y., Jin, Y., & Yang, E. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.05.622019
Obermeier, M., Esparza-Mora, M. A., Heese, O., Cohen, N., Varma, S. J., Tober‐Lau, P., Hartl, J., Kurth, F., Berman, J. G., & Ralser, M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.09.622705
The Effects of COVID-19 on Antifungal Prescribing in the UK—Lessons to Learn
Pates, K. M., Shang, Z., Jabbar, R., Armstrong-James, D. P. H., Schelenz, S., Periselneris, J. N., Arcucci, R., & Shah, A. (2024) · Journal of Fungi · doi:10.3390/jof10110787
Unprecedented fungal infections and systematization of superficial mycosis: the immunity paradigm
Leite, G. G. V. R., & Damasceno, C. A. V. (2022) · Reviews in Medical Microbiology · doi:10.1097/mrm.0000000000000316
“Copyright © 2022 Wolters Kluwer Hea dissemination to bloodstream is the critical step which convert these fungi species to lethal organisms that kill around one million people worldwide each year [10].”
Laboratorio Central de Salud Pública, A.-P., Aguilar, G., Araujo-López, P., Laboratorio Central de Salud Pública, A.-P., Lird, G., Argüello, R., & Blasco, R. (2025) · IATREIA · doi:10.17533/udea.iatreia.309
MDR in Candida: The Real Storm
Srivastava, P., Tiwari, S., Kumar, M., Murhekar, M. V., & Dwivedi, G. R. (2024) · Springer eBooks · doi:10.1007/978-981-97-4909-6_4
Recent Advances in the Management of Aspergillosis
Gupta, C., & Dar, S. A. (2024) · Springer eBooks · doi:10.1007/978-981-97-4909-6_16
Proteomics and Its Application to the Human Pathogenic Fungus Aspergillus fumigatus
Krüger, T., & Kniemeyer, O. (2024) · The mycota · doi:10.1007/978-3-031-64853-3_11
Ameen, H. M., Athira, A. S., Jayadev, A., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5322551/v1
Charoonrochana, N., Jinawath, N., Santanirand, P., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-80374-6
Teng, P., Liu, Y., Zhang, X., Luan, N., Han, X., & Liu, X. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s496441
Burden of Invasive Candidiasis in West Africa: A Systematic Review and Meta-Analysis
Diallo, S. N., Yerbanga, I. W., Zango, S. H., Montesinos, I., Denis, O., Robert, A. R., Bamba, S., & Rodriguez‐Villalobos, H. (2024) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2024.1212023 · Cited by 1
Guimarães, J. G., de Campos, G. Y., Machado, M. P., Brito, P. K. M. O., dos Reis, T. F., Goldman, G. H., Palma, P. V. B., Fraga‐Silva, T. F. D. C., Cavallini, D. C. U., Venturini, J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.12.628200
Safitri, D., Apriyanto, D. R., Apriyanto, D. R., et al. (2024) · COMSERVA Jurnal Penelitian dan Pengabdian Masyarakat · doi:10.59141/comserva.v4i8.2754
The Significance of Vaccines in Mitigating Emerging Infectious Diseases: A Comprehensive Review
ALNAKHLI, R. H., NAGEI, S. H. A., Alotaibi, A. S., ATAIFI, H. I. Y., Al-Mutairi, M. O., Mutairi, M. S. A., Ghashum, R. Q. A., Alhakami, B. A., Hakimi, A. A., Alshammari, S. H., et al. (2024) · Journal of Ecohumanism · doi:10.62754/joe.v3i8.5543
Development of C. albican Anti-attachment Inkjet 3D Printing Ink, via High Throughput Screening
Yong, L. X., Zhou, Z., Vallières, C., He, Y., Crucitti, V. C., Alexander, M. R., Avery, S. V., Wildman, R. D., & Irvine, D. J. (2025) · Mechanisms and machine science · doi:10.1007/978-3-031-81673-4_33
Rondón-Carvajal, J., Gil-González, M., Ruiz-Giraldo, S., Pinzón, M. A., & Gómez, J. C. C. (2025) · Cureus · doi:10.7759/cureus.76808 · Cited by 1
Examining Itraconazole Gel’s Effectiveness in Treating Fungal Dermatological Condition
Sawant, A., Nikam, P. N., Tupe, P. N., & Pawer, R. (2025) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-22927
Achan, B., Musinguzi, B., Itabangi, H., et al. (2025) · IJID Regions · doi:10.1016/j.ijregi.2024.100562
Bohner, F. (2024) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.12031
(2000) · Time to knit · doi:10.1016/s0246-0378(24)42754-1
(2000) · Time to knit · doi:10.1016/s1637-5017(22)85263-7
Prevalence of Fungal Infections that isolated from different sites in Diyala Province / Iraq
Mohammed, N. A., Fadhil, N. M., & Ahmed, A. D. (2024) · Al-Kufa University Journal for Biology · doi:10.36320/ajb/v16.i1.15245
Fungal Diagnostic Assays That Clinicians Need in Resource-Limited Countries
Mardani, M. (2024) · Archives of Clinical Infectious Diseases · doi:10.5812/archcid-158573
Labonté, A. L., Nadia, N. A. C., Cédric, Y., Ekpo, A. I., Aziz, M., & Paul, D. J. (2025) · Asian Journal of Biological Sciences · doi:10.3923/ajbs.2025.443.451
Mohammed, I. A., & Jonnalagadda, S. (2025) · Pharmaceutical Nanotechnology · doi:10.2174/0122117385341583250119054309
Wani, W. A., Alajmi, M. F., Hussain, A., & Wani, I. A. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781837678891-00001
The Fungal Susceptibility Mechanism of Inborn Errors of Immunity and Novel Antifungal Therapies
陈, 香. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.151302
Enhanced Computational and Experimental Approaches for Comparative Analysis of the Human MycobiomePreprint
Begum, N., Lee, S., Almeida, M., Engstrand, L., Patel, S. V. C., Uhlén, M., Ehrlich, S. D., Shoiae, S., & Moyes, D. L. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.09.637295
Pharmacokinetics of nanoparticles for infectious diseases
Dash, P., Halder, J., Rajwar, T. K., Pradhan, D., Das, C., Rai, V., Kar, B., Ghosh, G., & Rath, G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-28836-4.00027-5 · Cited by 1
Karadzas, M. T., Michel, A. H., Mosbach, A., Giannakopoulos, G., McGettigan, R., Scalliet, G., & Kornmann, B. (2025) · eLife · doi:10.7554/elife.105333
The Potential Antifungal Activity of the Developed Palladium NanoparticlesPreprint
l, H. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5101909
Busch, R. J., Doty, C., Mills, C. A., Latifi, F., Herring, L. E., Konjufca, V. H., Carvallo, F., Boluarte, T., & Vargas-Muñiz, J. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.25.640155
You, Z., Yan, Y., Fu, T., Yang, X., Li, Z., Zhou, L. J., & Zang, F. (2025) · Infection and Drug Resistance · doi:10.2147/idr.s507944 · Cited by 1
Hafeez, A., Mushtaq, M., Hanif, M., Saadia, H., Kakar, K., Ejaz, H., Moeezullah, S., Karim, S., Pushparaj, P. N., Mustafa, M. Z., et al. (2025) · Journal of King Saud University - Science · doi:10.25259/jksus_169_2024 · Cited by 2
Das, R., Sahid, S. H., & Noor, J. (2024) · International Conference on Information and Communication Technologies and Development (ICTD) · doi:10.1145/3700794.3700806
“Moreover, it can also become deadly if not identified, and treated properly at an early stage [2, 10].”
Macrophage ferroptosis inhibits Aspergillus conidial killing in lung transplantationPreprint
Matthaiou, E. I., El‐Hafeez, A. A. A., Sharifi, H., Chatterjee, P., Zinter, M. S., Johansson, P. K., Dhillon, E., Chiu, W., Qian, J., Shaller, B. D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.13.643092 · Cited by 3
dos Reis, T. F., Delbaje, E., Pinzan, C. F., Bastos, R. W., Ackloo, S. Z., Fallah, S., Laflamme, B., Robbins, N., Cowen, L. E., & Goldman, G. H. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.03318-24 · Cited by 2
“Aspergillosis triggers several clinical conditions with variable prevalence and mortality, depending on the condition of the host and their immune system (8).”
Ansari, A. A., Phulpoto, A. H., Lal, S., Mughal, A. A., & Talpur, M. M. A. (2025) · Journal of Microbiological Sciences · doi:10.38211/jms.2025.04.66
“It was noted that peoples using catheters have developed 26.5% UTIs with candida (Cortese, Wagner, Tierney, Devine, & Fogarty, 2018).”
InfluentialMolecular Identification of Aspergillus spp. in Patients with Clinical Symptoms of Tuberculosis
Asriany, S., Massi, M. N., Rasita, Y. D., Ilyas, M., Hamid, F., & Muslich, L. T. (2025) · International Journal of Mycobacteriology · doi:10.4103/ijmy.ijmy_208_24 · Cited by 1
Almada, A. C., Mereles-Rodríguez, B., Chade, M. E., et al. (2025) · Journal of Fungi · doi:10.3390/jof11040245
“The main etiological agents are dermatophytes and yeast-like fungi of the genera Candida spp. and Malassezia spp. [1–4].”
PREVALENCE OF SKIN MYCOSES IN GANJA, AZERBAIJAN REPUBLIC
oglu, M. A. H. (2025) · Актуальні проблеми сучасної медицини Вісник Української медичної стоматологічної академії · doi:10.31718/2077-1096.25.1.56
A novel pan-fungal screening platform for antifungal drug discovery: proof of principle study
Inman, R., Warris, A., & Bignell, E. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01328-24
“These factors, as well as a lack of sensitive diagnostic tools and an increasing number of at-risk patients, contribute to an alarmingly high global fungal disease burden (3).”
Rassan, M. A., Ewaisha, R., Zeitoun, H., & Shehat, M. G. (2025) · Letters in Applied Microbiology · doi:10.1093/lambio/ovaf055
Celier, A., & Weiss, N. (2025) · EMC - Neurologia · doi:10.1016/s1634-7072(25)50367-7
Choudhary, A., Prajapati, J., Patel, B., Viradiya, R. H., Patel, H. D., Goswami, D., & Chikhalia, K. H. (2025) · ChemistrySelect · doi:10.1002/slct.202405674 · Cited by 1
The Other Side of the Coin of Pulmonary Fungal Diseases: Toward New Paradigms
López, M. C., & Briseño, D. M. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202504-0803ed
Freitas-Xavier, R., Santos, E. M., da Silva, C., & Maciel, I. A. F. (2025) · Infectious diseases · doi:10.5772/intechopen.1010270
Effect of bacterial symbiosis on filamentous fungal adaption to environmental stressorsPreprint
Kumureeba, L., Musinguzi, B., Kassaza, K., Kasajja, A., Achan, B., Ampaire, L., & Itabangi, H. (2025) · Research Square · doi:10.21203/rs.3.rs-6506101/v1
Uncovering the Predisposing Factors of Mucormycosis: Insights from Systematic Review
Ravindhiran, R., Chidambaram, K., Subramanian, A., Velayutham, S., Ramar, M., & Dhandapani, K. (2025) · Indian Journal of Microbiology · doi:10.1007/s12088-025-01491-y · Cited by 1
Chabhadiya, B. K., Naik, H. N., Mohite, B. A., et al. (2025) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2025.2503979
“Almost one billion individuals are affected by microbial illnesses globally, which can range in severity from minor to perhaps fatal (Bongomin et al., 2017; Wu et al., 2022;).”
Life-saving and Limb-saving in Case of Primary Cutaneous Mucormycosis of the Lower Limb
Jagan, K., Khan, S. L. S. A., & Safwan, A. M. (2025) · Kerala Surgical Journal · doi:10.4103/ksj.ksj_3_25
Bourcier, T., Bouheraoua, N., Koestel, E., et al. (2025) · Encyclopédie médico-chirurgicale. Ophtalmologie · doi:10.1016/s0246-0343(24)47210-9
Vulvovaginal Candidiasis: Pathophysiology, the Role of Biofilms, and Emerging Therapeutics
Murali, P., Slate, A. J., Kean, R., & Johnston, W. (2025) · Springer series on biofilms · doi:10.1007/978-3-031-93315-8_5
Photo Quiz: A cutaneous fungal infection with discordant biomarker results—a diagnostic challenge
Dumont, G., Chaib, S., Bontemps, E., et al. (2025) · Journal of Clinical Microbiology · doi:10.1128/jcm.02075-24
Oladele, R. O., Ayanlowo, O. O., Ocansey, B. K., & Stone, N. R. H. (2025) · Cambridge University Press eBooks · doi:10.1017/9781009052733.065
Self-citationEchoes of infection: radial EBUS unveils invasive pulmonary aspergillosis
Vijay Balaji, K., Chauhan, N. K., Dutt, N., et al. (2025) · BMJ Case Reports · doi:10.1136/bcr-2024-264471
Tolo, F. D. N., Essono, M. D., Alio, H. M., & Enama, S. E. (2025) · Open Journal of Stomatology · doi:10.4236/ojst.2025.156012
Liquid chromatography-tandem mass spectrometry for quantifying seven antifungal drugs in human serum
Cui, Y., Shi, X., Jin, J., & Zhang, Y. (2025) · Journal of Liquid Chromatography & Related Technologies · doi:10.1080/10826076.2025.2510339
2-ethyl-1-hexanol: a promising molecule against priority fungal pathogens
Marcomini, E. K., Rezende, P. S. T., Gomes, J., Leite, C. R., de Oliveira, K. M. P., Pomini, A. M., Svidzinski, T. I. E., & Negri, M. (2025) · Journal of Applied Microbiology · doi:10.1093/jambio/lxaf165 · Cited by 2
Defungi Dataset Classification: A Comparative Study of Machine Learning and Cnn ModelPreprint
Okyay, T. M., Mergen, B., & Koldaş, M. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5343518
Tawfeek, M. M. M., Tohamy, D. M. A., Ahmed, H. M. A. H., et al. (2025) · Journal of the Egyptian Ophthalmological Society · doi:10.4103/ejos.ejos_65_24
Sukted, J., Junsuntonpass, A., Homchan, A., Mongkolsuk, S., Pakotiprapha, D., & Matangkasombut, O. (2025) · Scientific Reports · doi:10.1038/s41598-025-12238-6
Yoon, C. J., Je, G., & Kim, K. W. (2025) · Tissue and Cell · doi:10.1016/j.tice.2025.103052
Baldin, C., Binder, U., Scheler, J., Werner, E., Gsaller, F., Bromley, M., & Haas, H. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1646661 · Cited by 1
Zehra, S. R., Zaka, S., Farooqi, J. Q., et al. (2025) · Laboratory Medicine · doi:10.1093/labmed/lmaf028
Parra-Fariñas, R., Alonso, M., Solis, P., Rodriguez, B., Tellado, Á. G., Perez, I. I., Belhassen‐García, M., & Pardo‐Lledías, J. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5380701
POLYMERASE CHAIN REACTION IN SERUM FOR DIAGNOSIS OF ASPERGILLOSIS
Мирчевска, Г. (2025) · Academic Medical Journal · doi:10.53582/amj255201m · Cited by 1
Wang, Y., Li, P., Huang, J., Jiang, R.-Y., Zhu, C., & Sun, S. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.01479-25
“Pathogenic fungal infections infect hundreds of millions of patients globally each year, causing at least 1.5 million deaths annually (2).”
InfluentialSam, A., Julius, N., & Koray, M. H. (2025) · Tropical Medicine and Health · doi:10.1186/s41182-025-00778-6
“Mycetoma is caused by a number of different fungal pathogens, including Madurella spp for mycetoma, whereas chromoblastomycosis is associated with dema-tiaceous fungi, such as Fonsecaea spp [9, 10].”
InfluentialHunutlu, F. Ç., Özkalemkaş, F., Ener, B., Demirayak, D., Çalışır, B., Öztop, H., Pınar, İ. E., Gürsoy, V., Ersal, T., Koca, T. G., et al. (2025) · Journal of Fungi · doi:10.3390/jof11090630 · Cited by 1
“Numerous factors influence this incidence, including geographical distribution, the presence and type of antifungal prophylaxis, physical conditions in the hospital, and the characteristics of the underlying hematological malignancy [3,4].”
Medical Mycology Education in Brazil: A Cross-Sectional Survey of Medical Schools
Pasqualotto, A. C., Aquino, V. R., Falci, D. R., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf540
“Our findings are consistent with prior concerns raised in the literature about the underrepresentation of fungal diseases in medical training worldwide, particularly in low-and middle-income countries [1, 2].”
InfluentialPatole, S. S., Dhivare, R. S., Rajput, S. S., & Patel, H. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5430952
Zhang, J., Ren, W., Deng, H., Zhang, Y., Gong, M., Bo, L., Li, B., & Li, C. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1652051
“Invasive pulmonary aspergillosis (IPA) is a lethal fungal infection with a mortality rate of approximately 30–80% (7, 8).”
Effects of novel organoantimony compounds on the fungal pathogen Cryptococcus neoformans
Cotton, K., Lieberman, J. A., Gerasimchuk, N., & Wozniak, K. L. (2025) · Journal of Medical Microbiology · doi:10.1099/jmm.0.002058 · Cited by 1
Martins, N. D. R. C., Ribeiro, R. C. B., Desmarais, M. O. L., Lourenço, A. L., da Silva, A. R., Almeida, T. D. C., Gonçalves, S. C. G., Ratcliffe, N. A., Andrade, I. M. G., Marins, L. M., et al. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118380
Maseda, E., Peláez, T., Aguilar, G., Martín‐Loeches, I., Benítez-Cano, A., Rodríguez, A. H., Zaragoza, R., Guinea, J., Aldecoa, C., & Suárez-de-la-Rica, A. (2025) · Revista Española de Anestesiología y Reanimación (English Edition) · doi:10.1016/j.redare.2025.501916 · Cited by 2
Fungal Pathogenesis and Virulence in the Anthropocene: Multidimensional Impacts of Climate Change
Araújo, G. R. D. S., & Frasés, S. (2025) · Current Clinical Microbiology Reports · doi:10.1007/s40588-025-00252-1
“The emergence of antifungal resistance and the discovery of novel pathogenic fungi necessitate a One Health approach that recognizes the interconnected nature of these threats across different domains [95, 112]”
Lovo, C. B., Ramos, I. V. G., Silva, L. D., Lopes, N. C., Durlacher, R. R., Rodrigues, R. S., Kuehn, C. C., Souza, E. B., Carvalho, C. M., & Matos, N. B. (2025) · Brazilian Journal of Biology · doi:10.1590/1519-6984.291553 · Cited by 1
Garg, A., Matos, G. S., Takemura, K., Haranahalli, K., Bhat, S. S., de Sá, N. P., Fernandes, C. M., Poeta, M. D., & Ojima, I. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118406 · Cited by 1
Advances in Fungal Infection Research: From Novel Diagnostics to Innovative Therapeutics
Rodrigues, C. F., & Černáková, L. (2025) · Journal of Fungi · doi:10.3390/jof11100693 · Cited by 1
“Invasive and superficial fungal infections continue to impose a significant global health burden, with rising morbidity and mortality rates particularly affecting immunocompromised populations [1,2].”
Biçer, M., Serçinoğlu, O., & Okur, T. (2025) · Celal Bayar Üniversitesi Fen Bilimleri Dergisi · doi:10.18466/cbayarfbe.1593863
Molecular attributes of intrinsically disordered regions in secretomes influence fungal pathogenesisPreprint
Mohapatra, A., Kadumuri, R. V., Sharma, A., Saju, A. P., Ramadasan, H., Agrawal, A., Sharma, V., & Chavali, S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.01.679754
Long, Z., Lu, L., Xian, G., Li, Z., Guo, M., Li, A.-G., Guan, Z., Ye, F., & Wang, Y. (2025) · Mycopathologia · doi:10.1007/s11046-025-01007-8
“Although most individuals are not prone to develop invasive fungal disease (IFD), immunocompromised individuals, including people living with HIV, cancer patients receiving chemotherapy, and organ transplant recipients, demonstrate heightened susceptibility to invasive infections [4].”
Molecular analysis of ERG11 gene in azole resistant Candida Species among immunocompromised patients
Salem, A. H., Mashaly, M. E.-S., Deeb, D. R. E., Agha, S., Eldegwi, M., & Elshaer, M. Y. S. (2026) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2026.101635
Walker, B. E., Bignell, E., & Andrianopoulos, A. (2025) · Access Microbiology · doi:10.1099/acmi.0.001057.v3
“Aspergillus fumigatus is a globally prevalent human fungal pathogen and has been flagged as a critical threat to human health by the World Health Organization [1, 2].”
Brandt, O., Otrofanowei, E., Dlova, N. C., et al. (2025) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15885
Silva, M. L., Lopes, F. E. S., Peixoto, P. H. S., Silva, L., Colares, P. P. R., da Silva, B. N., Souza, P. F. N., Montenegro, R. C., Castelo‐Branco, D. D. S. C. M., Lorenzón, E. N., et al. (2025) · Future Microbiology · doi:10.1080/17460913.2025.2574812 · Cited by 1
Yuliana, Sufiawati, I., Dewi, I. M. W., & Hartantri, Y. (2025) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s536437 · Cited by 2
“11,12 Although the clinical impact is significant, studies on the types of Candida species and their antifungal resistance patterns in HIV-positive patients in Indonesia, specifically in West Java, remain very limited.”
The Role of the Immune System Against Neuromycotic Infections
Vicente, V., Tostes, A. F., & Shieh, I. C. (2025) · Fungal biology · doi:10.1007/978-3-032-06014-3_7
Clinical Aspects of Fungal Infections
Loreto, É. S., Tondolo, J. S. M., & Zanette, R. A. (2025) · Fungal biology · doi:10.1007/978-3-032-06014-3_6
Epidemiology and Mechanisms of Antifungal Resistance in Common Fungal Infections
Rizvi, M., Fatima, N., & Sami, H. (2025) · Fungal biology · doi:10.1007/978-3-032-06014-3_3
Fungal Infections Associated with Primary and Secondary Immunodeficiencies
Galván-Hernández, A. K., Gómez-Gaviria, M., & Mora-Montes, H. M. (2025) · Fungal biology · doi:10.1007/978-3-032-06014-3_2 · Cited by 2
Mphande, F. A. (2025) · Springer eBooks · doi:10.1007/978-981-95-0618-7_8 · Cited by 1
Awareness and perception of invasive fungal diseases among the Nigerian population
Makanjuola, O. B., Udoh, U. A., Akinlawon, D. O., Ogunsola, F. T., & Oladele, R. O. (2025) · Journal of Public Health in Africa · doi:10.4102/jphia.v16i1.1323
Self-citationHarnessing host-derived biomarkers for personalized diagnosis of invasive fungal infections
Scott, J., Machado, A., Carvalho, A., & Cunha, C. (2025) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2025.2587613 · Cited by 2
Distinct Ire1-driven transcriptional responses control morphogenesis in Candida albicansPreprint
Stack-Couture, S., Marsiglio-Librais, G. N., Lung, B., Genereaux, J. L., Halder, V., Dumeaux, V., Shapiro, R. S., & Lajoie, P. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.13.688365
Metadata
- Authors
- Bongomin, F., Gago, S., Oladele, R., & Denning, D.
- Affiliations
- University of Manchester (GB)
- Corresponding author
- Denning, David
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2017-10-18
- Volume
- 3
- Issue
- 4
- Pages
- 57
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC5753159
- OpenAlex
- W2767031614
- Semantic Scholar
- a31bc4c8c2356520b0818d41b5c4a2e2091b6f32
- Cited by
- 2,953
- References
- 192
- Citations by year
- 2026: 280 · 2025: 388 · 2024: 518 · 2023: 436 · 2022: 427 · 2021: 370 · 2020: 307 · 2019: 156 · 2018: 67 · 2017: 2
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/P002390/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
- Keywords
- fungal infection, disease burden estimation, prevalence, chronic pulmonary aspergillosis, cryptococcal meningitis, invasive candidiasis, Pneumocystis carinii pneumonia, invasive aspergillosis, disseminated histoplasmosis, fungal asthma, fungal keratitis, HIV/AIDS, antifungal therapy, estimation accuracy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.